疏血通注射液辅助治疗进展性脑梗死的临床观察

目的:观察疏血通注射液治疗进展性脑梗死的疗效和安全性。方法:将86例进展性脑梗死患者按就诊日期分为治疗组(50例)和对照组(36例)。治疗组患者给予疏血通注射液6 ml加入0.9%氯化钠注射液250 ml中静脉滴注,qd;对照组患者给予香丹注射液30 ml或血栓通注射液30 ml加入0.9%氯化钠注射液250 ml中静脉滴注,qd。两组患者均用药14 d。观察两组患者的神经功能缺损程度评分、血液流变学及凝血功能指标,并比较两组患者的疗效及不良反应发生情况。结果:治疗后,治疗组患者的神经功能缺损评分显著低于对照组,总有效率(92.00%)显著高于对照组(77.70%),凝血酶原时间和活化部分凝血活酶时间显著长于对照组,而全血黏度、血浆黏度、血浆纤维蛋白原浓度和血小板聚集率均显著低于对照组,两组比较差异均有统计学意义(P<0.05)。两组患者均未见不良反应发生。结论:疏血通注射液治疗进展性脑梗死安全、有效。

Clinical Observation of Adjunctive Treatment of Shuxuetong Injection for Progressive Cerebral Infraction

OBJECTIVE： To observe therapeutic efficacy and safety of Shuxuetong injection in the treatment of progressive cerebral infraction. METHODS： 86 patients with progressive cerebral infraction were divided into treatment group （50 cases） and control group （36 cases） according to clinic date. Treatment group was given Shuxuetong injection 6 ml added into 0.9% Sodium chloride injection 250 ml intravenously once a day; control group was given Xiangdan injection 30 ml or Xueshuantong injection 30 ml added into 0.9% Sodium chloride injection 250 ml intravenously once a day. Treatment course of 2 groups lasted for 14 days. The neurologic impairment score, hemorrheology and coagulation function were observed in 2 groups. Therapeutic effect and adverse drug reaction were compared between 2 groups. RESULTS： After treatment, neurologic impairment score of treatment group was significantly lower than that of control group; total effective rate （92.00%） of treatment group was significantly higher than that of control group （77.70%）; prothrombin time and activated partial thromboplastin time of treatment group were longer than those of control group, and blood and plasma viscosity, plasma fibrinogen concentration and thrombocytic aggregation of treatment group were significantly lower than those of control group; there was statistical significance （P〈0.05）. No ADR was observed in 2 groups. CONCLUSIONS： Shuxuetong injection is safe and effective for progressive cerebral infraction.